JPMorgan lifts target to USD 300.00 for Biogen stock

Published on 10/15/2026 at 20:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 28, 2026. Biogen stock costs EUR 211.05 on October 15, 2026, up 2.38 percent versus the Tradegate close of October 14, 2026.

Analyst view and market date

JPMorgan moved its Biogen target from USD 210.00 to USD 300.00 on October 12, 2026.
Biogen is scheduled to report third-quarter results on October 28, 2026.
Biogen stock costs EUR 211.05 at Lang & Schwarz on October 15, 2026 at 8:31 p.m. CEST, 2.38 percent above the Tradegate close of October 14, 2026.
Biogen had a USD 35.0 billion market capitalization as of October 15, 2026.

Biogen Inc., US09062X1037, Illustration mit AI erstellt.

JPMorgan upgraded Biogen to overweight from neutral and raised its price target from USD 210.00 to USD 300.00 on October 12, 2026, according to CNBC. The new target is 26.74 percent above Biogen's USD 236.70 Nasdaq quote at 2:34 p.m. ET on October 15, 2026. At 8:31 p.m. CEST, the stock was trading at EUR 211.05 at Lang & Schwarz, 2.38 percent above the Tradegate close of October 14, 2026.

October results set the calendar

Biogen's next scheduled reporting date is October 28, 2026. The company said it will publish third-quarter financial results before the US market opens, followed by a management webcast at 8:30 a.m. ET, according to its investor release dated September 16, 2026, published by Biogen. The date gives the stock a defined near-term calendar event after JPMorgan's target increase.

Stock position after hours

The Nasdaq quote stood at USD 236.70 at 2:34 p.m. ET on October 15, 2026, up 1.66 percent from USD 232.83. Trading volume was 951,075 shares against an average of 997,837 shares. The 52-week range was USD 138.00 to USD 240.99, placing the quote 1.78 percent below the high.

Valuation and market size

Biogen's market capitalization was USD 35.0 billion as of October 15, 2026, while its price-to-earnings ratio was 41.90. The current valuation leaves the JPMorgan target 26.74 percent above the Nasdaq quote, using the two values in the same currency. Biogen operates in healthcare and drug manufacturing, with neurological and neurodegenerative treatments at the center of its business.

Comparison with peers

Biogen Inc.: plus 2.38 percent, P/E 41.90, market capitalization USD 35.0 billion

Regeneron Pharmaceuticals (Nasdaq, USD): plus 2.85 percent, P/E 19.80, market capitalization USD 82.4 billion

Vertex Pharmaceuticals (Nasdaq, USD): plus 2.10 percent, P/E 29.60, market capitalization USD 129.0 billion

Price after the Xetra session

The euro quote placed Biogen above its October 14 Tradegate close while the US listing was still in regular trading. The different venue currencies make the Nasdaq figures a separate market reference, not a second euro performance measure. The further course of trading is shown by the continuously updated real-time quote of Biogen stock.